50
Participants
Start Date
April 19, 2019
Primary Completion Date
December 2, 2022
Study Completion Date
August 31, 2025
ruxolitinib
Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. it's believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body
H. Lee Moffitt Cancer Center, Tampa
Cleveland Clinic, Cleveland
Medical College of Wisconsin, Milwaukee
Huntsman Cancer Institute, Salt Lake City
City of Hope Cancer Center, Duarte
Fred Hutchinson Cancer Center, Seattle
Massachusetts General Hospital, Boston
Collaborators (1)
Incyte Corporation
INDUSTRY
Massachusetts General Hospital
OTHER